Haemonetics (NYSE:HAE) Price Target Raised to $90.00

Haemonetics (NYSE:HAE) had its target price increased by equities research analysts at Mizuho from $75.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Mizuho’s price objective would suggest a potential upside of 11.21% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Haemonetics in a research note on Monday, December 8th. CJS Securities raised Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Raymond James Financial restated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research report on Friday, November 14th. Citigroup decreased their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, October 7th. Finally, Robert W. Baird raised their price objective on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $84.10.

Haemonetics Stock Performance

NYSE:HAE opened at $80.93 on Wednesday. The company has a market cap of $3.79 billion, a P/E ratio of 23.66, a P/E/G ratio of 1.52 and a beta of 0.30. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company’s 50-day moving average price is $66.63 and its 200-day moving average price is $64.58. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the prior year, the firm earned $1.12 EPS. Haemonetics’s quarterly revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, sell-side analysts forecast that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Large investors have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new stake in Haemonetics in the third quarter valued at approximately $233,000. CIBC Private Wealth Group LLC increased its holdings in Haemonetics by 69.3% in the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 448 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Haemonetics during the 3rd quarter worth about $251,000. Danske Bank A S purchased a new position in shares of Haemonetics in the 3rd quarter valued at about $665,000. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Haemonetics by 20,925.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 837 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.